Published in Lancet on July 25, 2009
The first decade of antiretroviral therapy in Africa. Global Health (2011) 1.27
Public sector services for the prevention of mother-to-child transmission of HIV infection: a micro-costing survey in Namibia and Rwanda. Bull World Health Organ (2013) 0.85
Improving adherence to antiretroviral treatment in Uganda with a low-resource facility-based intervention. Glob Health Action (2014) 0.75
Obama administration may flat-line funding for PEPFAR. Lancet (2009) 1.82
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS (2007) 5.97
Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet (2002) 5.80
Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr (2004) 4.58
Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections. Lancet (2004) 4.13
Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol (2005) 3.00
Expanding HIV care in Africa: making men matter. Lancet (2009) 2.54
Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda. AIDS Patient Care STDS (2005) 2.48
Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet (2002) 2.36
Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther (2006) 2.02
Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med (2014) 2.00
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis (2008) 1.98
Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr (2012) 1.78
T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis (2005) 1.63
Impact of HIV antiretroviral therapy on depression and mental health among clients with HIV in Uganda. Psychosom Med (2012) 1.58
High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2004) 1.58
Factors associated with intention to conceive and its communication to providers among HIV clients in Uganda. Matern Child Health J (2012) 1.50
Diminishing availability of publicly funded slots for antiretroviral initiation among HIV-infected ART-eligible patients in Uganda. PLoS One (2010) 1.35
Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe. PLoS One (2012) 1.33
HIV-specific IL-10-positive CD8+ T cells are increased in advanced disease and are associated with decreased HIV-specific cytolysis. J Immunol (2006) 1.26
Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. AIDS (2007) 1.26
A qualitative analysis of the economic impact of HIV and antiretroviral therapy on individuals and households in Uganda. AIDS Patient Care STDS (2009) 1.24
Factors associated with condom use among HIV clients in stable relationships with partners at varying risk for HIV in Uganda. AIDS Behav (2010) 1.19
Coinfection with Schistosoma mansoni is associated with decreased HIV-specific cytolysis and increased IL-10 production. J Immunol (2005) 1.17
A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda. AIDS Res Hum Retroviruses (2008) 1.16
Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. Antivir Ther (2010) 1.15
Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors. J Acquir Immune Defic Syndr (2007) 1.13
Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Curr Opin HIV AIDS (2013) 1.12
Global threat from drug resistant HIV in sub-Saharan Africa. BMJ (2012) 1.11
Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. Antivir Ther (2009) 1.08
Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis (2012) 1.07
First trial of the HIV-1 vaccine in Africa: Ugandan experience. BMJ (2002) 1.06
Validation of World Health Organisation HIV/AIDS clinical staging in predicting initiation of antiretroviral therapy and clinical predictors of low CD4 cell count in Uganda. PLoS One (2011) 1.06
Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. Pediatr Infect Dis J (2011) 1.05
Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children. AIDS Res Hum Retroviruses (2013) 1.03
Understanding the influence of depression on self-efficacy, work status and condom use among HIV clients in Uganda. J Psychosom Res (2010) 1.03
Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity. J Clin Virol (2008) 0.99
The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda. AIDS Res Ther (2009) 0.98
Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine. AIDS Res Hum Retroviruses (2009) 0.97
Barriers to Initiation of Pediatric HIV Treatment in Uganda: A Mixed-Method Study. AIDS Res Treat (2012) 0.97
A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria. PLoS One (2013) 0.97
Decreased serum opsonic activity against Streptococcus pneumoniae in human immunodeficiency virus-infected Ugandan adults. Clin Infect Dis (2003) 0.97
Depression in the pathway of HIV antiretroviral effects on sexual risk behavior among patients in Uganda. AIDS Behav (2012) 0.97
Mechanisms of apoptosis of T-cells in human tuberculosis. J Clin Immunol (2005) 0.97
The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children. AIDS (2010) 0.96
Orphanhood predicts delayed access to care in Ugandan children. Pediatr Infect Dis J (2009) 0.94
Human immunodeficiency virus-specific responses in adult Ugandans: patterns of cross-clade recognition. J Virol (2005) 0.92
Oropharyngeal colonization by Streptococcus pneumoniae among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility. Int J Infect Dis (2006) 0.90
Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period. AIDS (2013) 0.90
A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLoS One (2010) 0.89
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. J Antimicrob Chemother (2008) 0.88
Response to antiretroviral therapy of HIV type 1-infected children in urban and rural settings of Uganda. AIDS Res Hum Retroviruses (2012) 0.86
Presence of distinct subsets of cytolytic CD8+ T cells in chronic HIV infection. AIDS Res Hum Retroviruses (2006) 0.84
Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. Pediatr Infect Dis J (2015) 0.83
Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults. Vaccine (2008) 0.83
Lessons from Africa. J Acquir Immune Defic Syndr (2010) 0.83
HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe. AIDS Res Hum Retroviruses (2014) 0.81
A Case of Cryptococcal Lymphadenitis in an HIV-Infected Child. AIDS Res Hum Retroviruses (2010) 0.80
Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy. AIDS Res Hum Retroviruses (2013) 0.80
HIV-1 drug resistance in antiretroviral-naive patients in sub-Saharan Africa. Lancet Infect Dis (2013) 0.79
Opportunities for improving the efficiency of paediatric HIV treatment programmes. AIDS (2015) 0.79
Role of antiretroviral therapy in improving food security among patients initiating HIV treatment and care. AIDS (2012) 0.78
Dynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART. BMC Infect Dis (2013) 0.78
Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study. Vaccine (2011) 0.77
HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-Saharan Africa. J Acquir Immune Defic Syndr (2017) 0.75
The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models. Am J Epidemiol (2015) 0.75
Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children. Pediatr Infect Dis J (2014) 0.75
Highly active antiretroviral therapy. BMJ (2004) 0.75
A qualitative exploration of the impact of HIV and ART on social disruption and household continuity in Uganda. Afr J AIDS Res (2011) 0.75
No need for apologies. J Acquir Immune Defic Syndr (2011) 0.75
Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis. AIDS (2016) 0.75
CD4 T cell activation as a predictor for treatment failure in Ugandans with Plasmodium falciparum malaria. Am J Trop Med Hyg (2006) 0.75